Page 3 - Peripheral Intervention News Today

BDX earnings call for the period ending September 30, 2021.

/PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced it has received 510(k) clearance...

BD Announces Second Fiscal Quarter Results; Reaffirms Fiscal 2021 Guidance - Second fiscal quarter revenues of $4.9 billion grew 15.4% on a reported basis. On a currency-neutral basis, revenues increased 12.2%. - BDs COVID-19 testing sales were $480 million, including BD Veritor™ Plus System revenues of $290 million. - BDs core growth led by strong growth in Medication Delivery Solutions (up 10.4%), Pharmaceutical Systems (up 15.4%), and Biosciences (up 16.3%) on a reported basis. - Second fi...

Share this article Share this article FRANKLIN LAKES, N.J., April 14, 2021 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the Pristine™ Long-Term Hemodialysis Catheter, a new hemodialysis catheter with a unique side-hole free symmetric Y-Tip™ distal lumen design. The Pristine™ Catheter will be available in the U.S. in May 2021...

BD Announces First Fiscal Quarter Results; Raises Fiscal 2021 Guidance - First fiscal quarter revenues of $5.315 billion grew 25.8% on a reported basis. On a currency-neutral basis, revenues increased 24.3%. - BDs COVID-19 testing sales of $867 million contributed 20.5 percentage points to revenue growth on a reported basis. This includes BD Veritor™ Plus System revenues of $688 million. - First fiscal quarter GAAP diluted earnings per share (EPS) increased 285% year-over-year to $3.35. - Adj...

FRANKLIN LAKES, N.J., Jan. 12, 2021 /PRNewswire/ -- BD , a leading global medical technology company, today reported, preliminary unaudited financial information for the first fiscal... | January 16, 2021